CONMED Corporation CNMD R2K

Q: What is the current share price of CONMED Corporation (CNMD)?

As of 2026-07-14 21:23 PDT, CONMED Corporation (CNMD) trades at $41.75 on NYSE. Its 52-week range is $32.11 to $55.60.

Q: What is the market capitalisation of CNMD?

CONMED Corporation (CNMD) has a market capitalisation of $1.26B on NYSE.

Q: What is the P/E ratio of CNMD?

CNMD trades at a trailing price-to-earnings (P/E) ratio of 23.59. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.03.

Q: Does CNMD pay a dividend?

CONMED Corporation (CNMD) currently offers a dividend yield of 2.30%.

Q: What is the return on equity (ROE) of CNMD?

CNMD has a return on equity (ROE) of 5.50%. Its return on capital employed (ROCE) is 5.10%.

Q: Is CNMD a good stock to buy?

This page provides a data-driven analysis of CONMED Corporation (CNMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://www.conmed.com

Company Profile ↓

$41.75

-16.28% 1Y

Mkt Cap$1.26B

P/E23.59

P/B1.03

Div. Yield2.30%

52W High$55.60

52W Low$32.11

Book Value$33.76

EPS (TTM)$1.77

Company Overview

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 23.6, below the sector median of 25.4.

Dividend Income

Offers a dividend yield of 2.30%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $1.37B (+5.2% YoY); net profit $47.05M.
Trailing 12 Months Year-on-year growth — revenue -1.3%, earnings +136.8%.
5-Year Trend Long-term compounding — revenue CAGR 4.4%, profit CAGR 8.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	4.36%
1 Year:	-1.30%

Compounded Profit Growth

5 Years:	8.84%
1 Year:	136.80%

Stock Price Performance

1 Year:	-16.28%
6 Months:	-2.70%
3 Months:	+8.55%
1 Month:	+21.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 41% of range

$32.11 $55.60

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)67.10 · Neutral

Price Performance

1M+21.33%

3M+8.55%

6M-2.70%

1Y-16.28%

Valuation vs Sector

P/E of 23.59 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

23.59

Industry PE

25.41

Forward P/E

8.72

PEG Ratio

1.84

Book Value

$33.76

Price to Book

1.03

P/S

0.76

EV/EBITDA

8.89

Dividend Yield

2.30%

Growth (CAGR)

Revenue 5Y

4.36%

Profit 5Y

8.84%

Revenue (YoY)

-1.30%

Earnings (YoY)

136.80%

Profitability & Returns

ROCE

5.10%

ROE

5.50%

ROA

3.71%

Profit Margin

4.00%

Op Margin

10.01%

Gross Margin

54.06%

EPS (Latest Qtr)

$0.09

EPS (TTM)

$1.77

Balance Sheet & Liquidity

Debt/Equity

0.85

Quick Ratio

0.90

Current Ratio

2.29

Debt

$860.87M

Total Assets

$2.31B

Current Assets

$670.59M

Working Capital

$377.88M

Ownership

Promoter Holding

0.43%

Chg in Prom Hold

-0.00%

FII / Inst Holding

116.04%

Chg in FII Hold

-0.07%

Financial Snapshot

Enterprise Value

$1.26B

Total Revenue (TTM)

$1.37B

EBITDA

$210.66M

Free Cash Flow

$125.87M

Operating Cash Flow

$142.63M

Shares Outstanding

30.11M

Gross Margin

54.06%

Payout Ratio

22.60%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CNMD CONMED Corporation R2K	41.75	23.59	$1.26B	2.30%	5.10%	5.50%	4.36%	8.84%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025
Revenue	-	-	-	-	-	-	-	-	-	186.57M	197.15M	190.12M	-	202.06M	212.82M	202.31M	-	218.38M	238.26M	233.59M	-	214.01M	157.78M	237.84M	-	232.68M	255.16M	248.83M	242.33M	277.19M	275.09M	295.47M	317.65M	304.58M	312.27M	332.10M	316.70M	321.26M	342.35M	337.93M
Gross Profit	104.03M	92.28M	93.50M	93.55M	102.38M	97.74M	102.42M	101.21M	106.96M	99.89M	104.65M	102.55M	123.96M	109.56M	116.27M	110.63M	132.66M	121.44M	131.19M	130.11M	141.97M	119.16M	71.93M	133.70M	135.51M	128.45M	141.42M	142.31M	135.99M	151.78M	151.62M	155.32M	170.69M	168.06M	171.97M	183.73M	179.00M	177.75M	188.32M	166.12M
Operating Income	-	10.95M	12.42M	14.84M	-	3.54M	7.68M	13.85M	-	-2.49M	12.78M	13.47M	-	17.28M	16.68M	11.52M	-	11.64M	18.66M	20.94M	-	13.17M	-21.25M	29.38M	-	20.08M	25.71M	26.71M	22.44M	24.46M	24.25M	12.70M	27.42M	30.30M	35.01M	47.11M	65.71M	15.96M	38.16M	11.88M
Net Income	11.34M	6.31M	7.46M	8.87M	7.85M	-2.27M	2.88M	7.34M	6.71M	-4.54M	6.14M	7.20M	46.70M	10.66M	8.72M	5.83M	15.65M	1.02M	5.70M	6.97M	14.93M	5.93M	-27.40M	6.85M	24.14M	9.86M	13.29M	14.95M	14.97M	-168.29M	46.15M	1.82M	13.73M	15.84M	19.71M	29.98M	48.98M	6.04M	21.42M	2.86M
Diluted EPS	0.41	0.23	0.27	0.32	0.28	-0.08	0.10	0.26	0.24	-0.16	0.22	0.26	1.65	0.37	0.30	0.20	0.54	0.04	0.19	0.23	0.49	0.20	-0.96	0.23	0.81	0.31	0.41	0.47	0.47	-5.65	1.48	0.06	0.43	0.50	0.63	0.96	1.57	0.19	0.69	0.09
R&D Expense	-	6.54M	7.50M	6.65M	-	8.26M	8.01M	8.35M	-	7.62M	8.04M	8.27M	-	7.71M	9.98M	14.12M	-	10.57M	11.81M	10.98M	-	10.12M	8.70M	9.94M	-	10.03M	11.32M	10.86M	10.67M	11.49M	12.77M	12.54M	13.57M	12.46M	13.59M	14.10M	13.56M	12.95M	14.14M	13.90M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	694.74M	713.72M	725.08M	767.14M	762.70M	740.05M	719.17M	763.52M	796.39M	859.63M	955.10M	862.46M	1.01B	1.05B	1.24B	1.31B	1.37B
Gross Profit	337.33M	365.38M	374.93M	405.84M	412.42M	404.06M	381.70M	408.33M	431.04M	469.11M	524.72M	460.30M	568.04M	571.25M	676.25M	733.03M	750.48M
Operating Income	28.27M	57.09M	8.27M	65.21M	56.51M	52.79M	51.17M	37.68M	46.94M	71.31M	79.11M	46.01M	109.72M	70.05M	120.60M	200.33M	102.62M
Net Income	12.14M	30.35M	752.00K	40.48M	35.94M	32.19M	30.50M	14.66M	55.49M	40.85M	28.62M	9.52M	62.54M	-80.58M	64.46M	132.42M	47.05M
Diluted EPS	0.42	1.05	0.03	1.41	1.28	1.16	1.09	0.52	1.97	1.41	0.97	0.32	1.94	-2.68	2.04	4.25	1.51
R&D Expense	31.84M	29.65M	28.65M	28.21M	25.83M	27.78M	27.44M	32.25M	32.31M	42.19M	45.46M	40.47M	43.56M	47.15M	52.60M	54.43M	55.88M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	985.77M	935.59M	1.08B	1.09B	1.10B	1.10B	1.33B	1.36B	1.37B	1.78B	1.75B	1.77B	2.30B	2.30B	2.31B	2.33B
Total Equity	540.22M	576.51M	586.56M	573.07M	607.00M	606.32M	581.30M	585.07M	580.58M	631.43M	662.27M	710.47M	709.04M	785.43M	745.54M	834.22M	962.68M	1.03B
Cash & Equivalents	11.81M	10.10M	12.42M	26.05M	23.72M	54.44M	66.33M	72.50M	27.43M	32.62M	17.51M	25.86M	-	-	-	-	-	-
Long Term Debt	-	-	85.18M	88.95M	160.80M	214.44M	240.20M	269.47M	488.29M	471.74M	438.56M	-	-	-	-	-	-	-
Total Liabilities	-	-	399.21M	362.52M	471.85M	484.19M	516.90M	516.63M	748.41M	726.53M	706.87M	1.06B	1.04B	980.58M	1.55B	1.47B	1.34B	1.29B
Current Liabilities	-	-	179.87M	131.18M	125.21M	111.27M	115.96M	119.72M	113.95M	150.00M	160.94M	188.09M	190.20M	196.65M	296.55M	310.73M	278.13M	315.04M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	25.03M	38.24M	102.99M	95.20M	80.95M	65.18M	50.92M	39.88M	65.57M	74.70M	95.13M	64.53M	-	33.37M	125.35M	166.97M	170.69M
Investing Cash Flow	-21.77M	-20.02M	-21.74M	-105.95M	-18.45M	-20.68M	-24.36M	-266.02M	-29.05M	-16.51M	-387.66M	-13.64M	-	-249.53M	-20.03M	-13.08M	-20.96M
Financing Cash Flow	-3.69M	-15.61M	-66.70M	11.35M	-31.30M	-26.39M	-12.62M	182.54M	-34.88M	-72.27M	300.88M	-52.06M	-	225.00M	-110.43M	-151.00M	-135.82M
Capital Expenditure	-21.44M	-14.73M	-17.55M	-21.53M	-18.45M	-15.41M	-15.01M	-14.75M	-12.84M	-16.51M	-20.07M	-13.01M	-	-21.79M	-19.03M	-13.08M	-19.81M
Free Cash Flow	3.58M	23.51M	85.44M	73.67M	62.50M	49.77M	35.91M	25.13M	52.72M	58.19M	75.07M	51.52M	-	11.58M	106.32M	153.88M	150.88M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	8.84M	-5.12M	2.88M	13.91M
Share Buybacks	0	22.98M	15.02M	3.92M	50.56M	16.86M	0	0	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	48.6%	51.2%	51.7%	52.9%	54.1%	54.6%	53.1%	53.5%	54.1%	54.6%	54.9%	53.4%	56.2%	54.6%	54.3%	56.1%	54.6%
Operating Margin %	4.1%	8.0%	1.1%	8.5%	7.4%	7.1%	7.1%	4.9%	5.9%	8.3%	8.3%	5.3%	10.9%	6.7%	9.7%	15.3%	7.5%
Net Margin %	1.7%	4.3%	0.1%	5.3%	4.7%	4.3%	4.2%	1.9%	7.0%	4.8%	3.0%	1.1%	6.2%	-7.7%	5.2%	10.1%	3.4%
ROE %	2.1%	5.2%	0.1%	6.7%	5.9%	5.5%	5.2%	2.5%	8.8%	6.2%	4.0%	1.3%	8.0%	-10.8%	7.7%	13.8%	4.6%
ROCE %	-	7.1%	1.0%	6.8%	5.8%	5.4%	5.2%	3.1%	3.9%	5.9%	5.0%	2.9%	7.0%	3.5%	6.1%	9.9%	5.1%

Shareholding Pattern

Insiders

0.43%

Institutions

116.04%

Public Float

116.54%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	16.03%	4.83M	$164.39M
2	Earnest Partners LLC	8.53%	2.57M	$87.55M
3	Vanguard Portfolio Management LLC	6.90%	2.08M	$70.74M
4	Fuller & Thaler Asset Management Inc.	5.45%	1.64M	$55.93M
5	Bank of America Corporation	4.66%	1.40M	$47.79M
6	Dimensional Fund Advisors LP	4.63%	1.39M	$47.46M
7	Vanguard Capital Management LLC	4.60%	1.38M	$47.15M
8	State Street Corporation	4.60%	1.38M	$47.15M
9	SEI Investments Co	3.34%	1.00M	$34.23M
10	Cooke & Bieler LP	3.28%	987.78K	$33.65M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CNMD

Google News Mon, 13 Jul 2026

CONMED (CNMD) Stock Trades Up, Here Is Why - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPX1VPRDVuNUxLWi1udXVRYkFEX001LVlvYW5JbDMyR0hXWXZ6QkdwbE1PUU1aME1nM2xqbkdGMVNXeEdnMlM0RHg4SzFvM2dfNGVIWmVldnc5U3g1TWQtV094NmkzOVd6S0l5SDJ0UFdkS0QyMTFpQ1phcHQzVE85WXdrUQ?oc=5" targe…

Google News Mon, 13 Jul 2026

Medtech Surges On Buyout Rumors; Who's Behind The Bid? - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE13NDUyT3hSRmpXaHdVN1dsRmd4cVdENTRud3JUNTlmY0ZRVUhweFhUNWFTR25fVWdNWjFUNmJKTFVzVTJySTE3MkJzZmNrS0lHeEFIdXpuNFZsRnUxWmFnc3F4NUdQWkRIdGNselNITTdNeDJFRTRhSg?oc=5" target="_blank">Medte…

Google News Sun, 12 Jul 2026

CNMD Stock Surges As Much As 10% After-Hours On Reports Of Private Equity Takeover Interest - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxNSmVyd3BKZktnMXFGVVVaZEExcE5qNnA3Y3hhNWZPb09HYmpLRDhhV1UwRng2Q0xLalNRZnJvelluc0EyZU51YnBGMDUxMkRjS1IwSktUTUpTOHQ0UTFzMzNLQXhQWFNQTHhnSTRTcFU4NGx1WlE3RTFZcnpDcVlrQi1EUlZ1aW9OWFlXRl…

Google News hu, 09 Jul 2026

CONMED (NYSE:CNMD) Stock Price Up 11.6% - Still a Buy? - MarketBeat

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNcE5JOE9iODZHbjlKWGY1ZkwtNklCRTZpNGlKdjdnWEFTRUtfOE96Snl0MDBVMHRLaUtrOWdVN2hLRmZoejFqNm0xTFBMZTUwOWg3S2VCWU1GQm1hMFhtUWlWRm5OT2Y4YW5Hal9TWl9RU1ZmODVOMXBvUTZqWW5iM2kxMGxRS0toanNLb0…

Google News Fri, 10 Jul 2026

CNMD Stock Pops As New CFO Arrives And Street Stays Cautious - timothysykes.com

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNRGZRSEQ5OVc5TnBlZHRvZVAwS0FHR203VE44dkF0ZDIwXzdZYk1ONXJHOHlmUlpsQmJKaUtMVmNxczJhUW5xTmpfMmkwY3lJb1BFTHV5cjM0NjFhYjhDU1NHdGdFTUx0SjY4aVNuZm01Ulg3czdZckxqZm5pdzBUejB6UkRGNTJUS3lB?o…

Google News Sat, 11 Jul 2026

CNMD Stock Surges As Much As 10% After-Hours On Reports Of Private Equity Takeover Interest - TradingView

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOTUMxM3IxUGoyMnQ0U1hSWVlvTHE2VHJuUWk0MlVvSTBsMV9WVXRwWkp4ZUE3ck5HdWp2QUNxeHFWUWRHR0EzTnZyUEswZUIxWFlOLTMtcFBYT0FYcHFjNC1nbnBQUDlzNWc1RDF4OHhEWUVUVHdCUUpaWlNoM0FRSndkMEVObXRUaVNmb3…

CNMD — Frequently Asked Questions

What is the current share price of CONMED Corporation (CNMD)?

As of 2026-07-14 21:23 PDT, CONMED Corporation (CNMD) trades at $41.75 on NYSE. Its 52-week range is $32.11 to $55.60.

What is the market capitalisation of CNMD?

CONMED Corporation (CNMD) has a market capitalisation of $1.26B on NYSE.

What is the P/E ratio of CNMD?

CNMD trades at a trailing price-to-earnings (P/E) ratio of 23.59. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.03.

Does CNMD pay a dividend?

CONMED Corporation (CNMD) currently offers a dividend yield of 2.30%.

What is the return on equity (ROE) of CNMD?

CNMD has a return on equity (ROE) of 5.50%. Its return on capital employed (ROCE) is 5.10%.

Is CNMD a good stock to buy?

This page provides a data-driven analysis of CONMED Corporation (CNMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

CONMED Corporation CNMD R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

CONMED (CNMD) Stock Trades Up, Here Is Why - Yahoo! Finance Canada

Medtech Surges On Buyout Rumors; Who's Behind The Bid? - Investor's Business Daily

CNMD Stock Surges As Much As 10% After-Hours On Reports Of Private Equity Takeover Interest - Stocktwits

CONMED (NYSE:CNMD) Stock Price Up 11.6% - Still a Buy? - MarketBeat

CNMD Stock Pops As New CFO Arrives And Street Stays Cautious - timothysykes.com

CNMD Stock Surges As Much As 10% After-Hours On Reports Of Private Equity Takeover Interest - TradingView

CNMD — Frequently Asked Questions

What is the current share price of CONMED Corporation (CNMD)?

What is the market capitalisation of CNMD?

What is the P/E ratio of CNMD?

Does CNMD pay a dividend?

What is the return on equity (ROE) of CNMD?

Is CNMD a good stock to buy?

Explore More